Skip to content

Effect of Hericium Erinaceus on Clinical Patients With Hearing Impairment

Effect of Hericium Erinaceus on Clinical Patients With Hearing Impairment and Possible Mechanisms

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03632512
Enrollment
80
Registered
2018-08-15
Start date
2018-05-18
Completion date
2020-06-30
Last updated
2018-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tinnitus

Keywords

Hericium erinaceus, Hearing

Brief summary

This study aims to investigate the effect of Hericium Erinaceus on clinical patients with hearing impairment and possible mechanisms. Subjects with hearing impairment will be enrolled and randomly divided into experimental or control group supplemented with Hericium Erinaceus (430 mg/kg/day) or placebo, respectively for eight months. Basic characteristics will be evaluated at baseline by questionnaire. The hearing, liver and kidney functions, and neurotrophic factors will be examined at baseline, 4th month and 8th month.

Detailed description

This study aims to investigate the effect of Hericium Erinaceus on clinical patients with hearing impairment and possible mechanisms. Subjects with hearing impairment will be enrolled. Inclusion criteria were 50 to 79 years old with symmetric sensorineural hearing loss, subjective sensorineural tinnitus, and all frequencies differed of ears less than 15 dB. Exclusion conditions were patients with abnormal liver and kidney function, normal hearing, severe and very severe hearing loss, no tinnitus or non-subjective sensorineural tinnitus, moderate or more cognitive impairment, patients unable to understand the details of this study or patients unable to co-examine, history of alcohol or drug abuse, history of high ambient noise exposure, bone tone air gap of pure tone hearing threshold greater than 10 dB, and audiogram 4 kHz air conduction threshold greater than 8 kHz, 20 dB airway threshold, hearing impairment before age 30, and inability to understand the details of this study. Participants will randomly divide into experimental or control group supplemented with Hericium Erinaceus (430 mg/kg/day) or placebo, respectively for eight months by a prospective, randomized, double-blind approach. Basic characteristics will be evaluated at baseline by questionnaire. The status of hearing, and CBC, GOT, GPT, BUN, Creatinine, NGF and BDNF expressions in blood will be examined at baseline, 4th month and 8th month.

Interventions

DIETARY_SUPPLEMENTHericium honey bolus

The subjects of the experimental group will be supplemented with Hericium Erinaceus honey bolus(430 mg/kg/day) for eight months.

DIETARY_SUPPLEMENTPlacebo honey bolus

The subjects of the control group will be supplemented with Placebo honey bolus(8 bolus/ day) for 8 months.

Sponsors

Providence University, Taiwan
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
50 Years to 79 Years
Healthy volunteers
No

Inclusion criteria

* Patients aged 50 to 79 years old with symmetric sensorineural hearing loss, subjective sensorineural tinnitus, and all frequencies differed of ears less than 15 dB.

Exclusion criteria

* Patients with abnormal liver and kidney function, normal hearing, severe and very severe hearing loss, no tinnitus or non-subjective sensorineural tinnitus, moderate or more cognitive impairment , patients unable to understand the details of this study or patients unable to co-examine, history of alcohol or drug abuse, history of high ambient noise exposure, bone tone air gap of pure tone hearing threshold greater than 10 dB, and audiogram 4 kHz air conduction threshold greater than 8 kHz, 20 dB airway threshold, hearing impairment before age 30, and inability to understand the details of this study.

Design outcomes

Primary

MeasureTime frameDescription
1.Change of Tinnitus status evaluates by Tinnitus handicap inventory (THI)Baseline, 4th month and 8th monthThe status of tinnitus will be evaluated by Tinnitus handicap inventory (THI). THI is divided into three categories, including the functional (12 questions), emotional (8 questions), and catastrophic (5 questions) subscore. A total of 25 questions are used. The answer will be divided into three levels (will, sometimes, will not), and be scored into 4, 2 and 0 point, respectively. The subscore of functional (12 questions), emotional (8 questions), and catastrophic (5 questions) are 48, 32, and 20, respectively. The highest total score is 100 points. The higher the score, the more the tinnitus is. The difference of score will be compared from the baseline with 4th and 8th month.
Change of Tinnitus severity evaluates by visual analog scale (VAS)Baseline, 4th month and 8th monthThe severity of tinnitus will be scored with a visual analog scale (VAS) from point 0 to point 10 by subject. The difference of score will be compared from the baseline with 4th and 8th month.
Changes of hearing obstacle average measure by Pure Tone Audiometry(PTA)Baseline, 4th month and 8th monthPure tone threshold of subjects will be measured by Pure Tone Audiometry (PTA) to evaluate the changes from baseline ageing hearing obstacle average (dB HL) with 4th and 8th month.
Changes of speech recognizing measure by Speech Audiometry.Baseline, 4th month and 8th monthThe Speech Audiometry is used to evaluate the changes of baseline speech recognizing (dB HL) and speech speech recognition rate(%) with 4th and 8th month.
Changes of NGF and BDNF levels of blood investigate by enzyme-linked immunosorbent assay (ELISA)Baseline, 4th month and 8th monthThe NGF and BDNF levels of blood will be analyzed by enzyme-linked immunosorbent assay (ELISA) to detect the presence of NGF and BDNF. The NGF and BDN levels will be quantitative by the optical density (OD) of the sample comparing to a standard curve, which is a serial dilution of a known-concentration solution of the target molecule. The difference of NGF and BDNF levels will be compared from the baseline with 4th and 8th month.

Countries

Taiwan

Contacts

Primary ContactYin-Ching Chan, PhD
ycchan@pu.edu.tw886921376777
Backup ContactJuen-Haur Hwang, MD, PhD
G120796@tzuchi.com.tw886928834922

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026